Quality of life Assessment introduction

Slides:



Advertisements
Similar presentations
HEA PTP: M207 Health Economics1 Measurement & Valuation of Health What is health? Why do we need to measure it? How can it be measured? Why do we need.
Advertisements

Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Scaling Session Measurement implies “assigning numbers to objects or events…” Distinguish two levels: we can assign numbers to the response levels for.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Elicitation Some introductory remarks by Tony O’Hagan.
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Quality of Life Assessment in Clinical Trials Adapted from Introduction to Clinical Trials Biostatistics.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
H EALTH R ELATED Q UALITY OF L IFE Fowad Khurshid PHCL
Rescuing Clinical Trial Data For Economic Evaluation
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
1 The Patient Perspective: Satisfaction Survey Presented at: Disease Management Colloquium June 22, 2005 Shulamit Bernard, RN, PhD.
Measuring Health Status
1 Patient values or values from the general public.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Al wakeel J, Bayoumi M, Al Ghonaim M, Al Harbi A, Al Swaida A, Mashraqy A.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
Outcome research 1 Outcome/ instruments selection Wei-Chu Chie Preventive Medicine.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
Overview of Health-Related Quality of Life Measures May 22, 2014 (1:00 – 2:00 PDT) Kaiser Methods Webinar Series 1 Ron D.Hays, Ph.D.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Statistical Issues in the Analysis of Patient Outcomes April 11, 2003 Elizabeth Garrett Oncology Biostatistics Acknowledgement: Thanks to Ron Brookmeyer.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
VCE HHD Unit 3 Outcome 1 Dot Point (Dt Pt) 1 (also transition slide for Unit 3 & 4) Health and Human Development.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Scaling Session Measurement implies assigning numbers to objects or events. In our case, the numbers “weight” responses to questions, so that saying “Yes”
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Epidemiology. Classically speaking Classically speaking EPI DEMO LOGOS Upon,on,befall People,population,man the Study of The study of anything that happens.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?
1 VAS, SG, TTO and PTO An Interactive Introduction.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
Global burden of diseases
Preference Assessment 1 Measuring Utilities Directly
Quality of Life Assessment
Prof. Dr. Jan J.V. Busschbach
The valuation of disease-specific questionnaires for QALY analysis
Health-definition, concepts and dimensions
PUBLIC HEALTH – INTRODUCTION HEALTH STATUS OF A POPULATION
Measuring outcomes Emma Frew October 2012.
Presentation transcript:

Quality of life Assessment introduction Jan J. v. Busschbach, Ph.D. www.xs4all.nl/~jannetvb/busschbach Department of Medical Psychology and Psychotherapy, Erasmus MC j.vanbusschbach@erasmusmc.nl +31 10 4087807 Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Jan.Busschbach@deviersprong.nl +31 164 632200

Quality of life “…. Health is physical, mental and social well-being and not merely the absence of disease or infirmity...” World Health Organization, 1947 Extending health to well-being: Quality of life What is the definition of quality of life?

Definitions of Quality of Life Quality of life is the degree of need and satisfaction within the physical, psychological, social, activity, material and structural area (Hörnquist, 1982). Quality of life is the subjective evaluation of good and satisfactory character of life as a whole (De Haes, 1988). Health related quality of life is the subjective experiences or preferences expressed by an individual, or members of a particular group of persons, in relation to specified aspects of health status that are meaningful, in definable ways, for that individual or group (Till, 1992). Quality of life is a state of well-being which is a composite of two components: 1) the ability to perform everyday activities which reflects physical psychological, and social well-being and 2) patient satisfaction with levels of functioning and the control of disease and/or treatment related symptoms (Gotay et al., 1992). An individual’s perception of their position in life in the context of the culture and values systems in which they live and in relation to their goals, expectations, standards and concerns (WHO Quality of life Groups, 1993).

No clear definition because: Many possible definitions Multi-dimensionally Subjective Related to society Researchers are free to choose The notion of measuring the quality of life could include the measurement of practically anything of interest to anybody. And, no doubt, everybody could find arguments supporting the selection of whichever set of indicators to be his choice (Andrews & Withy, 1976, page 6)

No clear definition because: Different origins of research Clinical decision making: Does the patient benefit from the treatment? Epidemiology (public health): what is the morbidity of the population? Health economics: Is it worth the money?

Common items in definitions: It is not the doctor who reports Quality of life is subjective…. “Given its inherently subjective nature, consensus was quickly reached that quality of life ratings should, whenever possible, be elicited directly from patients themselves. “ (Aaronson, in B Spilker (Ed): Quality of life and Pharmacoeconomics in Clinical Trails, 1996, page 180) Reports between proxies and patients vary.

Common items in definitions: Health related Multidimensional Physical, psychological, social Questionnaires Standardize questions and response Reproducible results: sciences Quantify subjectivity Operational defined Like IQ and temperature.

How to measure quality of life form a clinical point of view? Choose items Are you able to walk one kilometer ? Do you feel depressed ? Choose response mode Binary yes / no Multiple (Likert) yes / at bid / hardly / no Continuous (Visual Analogue Scale) Always ————X—— Never Combine items to dimensions of quality of life Sum up the items belonging to one dimension Rescale sum on a scale from 0 to 100

Quality of life form a clinical point of view: profiles

The problem of multidimensionality What if outcome conflict e.g: better mobility, but worse roll emotional On has to weight or combine outcomes What if some patients dies? Cancer therapy Better quality of life, but higher mortality Weight quality of life with mortality

Time Without Symptoms of disease and subjective Toxic effects of treatment TWiST Developed by Gelber (statistician) In search for a typical “cancer” problem Often prolonged life but also a reductions in quality of life At the beginning (side effects) At the end Only count the days without symptoms of disease and subjective toxic effects of the treatment

Time Without Symptoms of disease and subjective Toxic effects of treatment

TWiST ignores differences in quality of life Healthy = 1 Sick (dead) = 0 There is more to life than sick/health Make scale 0..1 Quality adjusted TWiST (Q-TWiST) Q-TWiST = QALY Quality Adjusted Life Year

QALY Analysis Count life years Value (V) quality of life (Q) 1 = Healthy 0 = Dead One dimension Adjusted life years (Y) for value quality of life QALY = Y * V(Q) Y: numbers of life years Q: health state V(Q): the value of health state Q Also called “utility analysis”

Which health care program is the most effective? A new cancer therapy Quality of life = 0.7 1.5 year survival QALY = Y x V(Q)  1.5 x 0.7  1.05 QALY The standard therapy Quality of life = 0.8 1.0 year survival 1.0 x 0.8  0.8 QALY

How to measure QoL for the calculation of QALYs? One needs a uni-dimensional value of quality of life Like the IQ-test measures intelligence Ratio or interval scale Difference between 0 and .8 must be 8 time higher than .1 Four popular methods have these pretensions Visual Analog Scale Time Trade-Off Standard Gamble Person trade-off

Value a health state You are in a wheelchair No pain or discomfort No psychosocial problems

Visual Analogue Scale X VAS From psychological research Normal health X VAS Also called category scaling From psychological research “How is your quality of life today ?” “X” marks the spot Response in centimeters Rescale to [0..1] Different anchor point possible: Normal health (1.0) versus dead (0.0) Best imaginable health versus worse imaginable health Dead

Time Trade-Off TTO Wheelchair With a life expectancy: 50 years How many years would you trade-off for a cure? Max. trade-off is 10 years QALY(wheel) = QALY(healthy) Y * V(wheel) = Y * V(healthy) 50 V(wheel) = 40 * 1 V(wheel) = .8

Standard Gamble SG Wheelchair Life expectancy is not important here How much are risk on death are you prepared to take for a cure? Max. risk is 20% 100% life on wheels = (100%-20%) life on feet V(Wheels) = 80% or .8

Values differ N = 103 students

Comparisons of valuation methods (1) Visual analogue scale Easy No trade-off: no relation to QALY No interval proportions Massive evidence Much from other social sciences Standard Gamble / Time trade-Off Less easy Trade-off: clear relation to QALY Interval proportions Much evidence Especially in health economics

Comparisons of valuation methods (2) Person Trade-Off Difficult Trade-off: unclear relation QALY Include egalitarian aspects of health care Unclear interval proportions Very little evidence Controversial results Extreme value compression

Patient values seem high Stensman Scan J Rehab Med 1985;17:87-99. Scores on a visual analogue scale 36 subjects in a wheelchair 36 normal matched controls Mean score Wheelchair: 8.0 Controls: 8.3

Response shift

Interpretation response shift Thentest = true value Saves trouble of pre-test But….is the post-test still true? Should we do a thenposttest as well? Does this say that patient can not judge their own health?

Which patient should we ask? Those with experience? Who are they? The amount of experience Length of experience Time since experience Strength of relation with patient No experience Friends No time at all Family Some time Long Self Now recently distant never All current patients

Quality of life in patients When should we ask? Which patients should we ask? Response shift Is a low quality of life a sign of a low physical functioning? an absence of the response shift?

The incomprehensible patient Keeps on coming back to the clinic Modifies social environment Passive in own goals Angry, depressed, suspicious Low quality of life

Adaptation and quality of life A low quality of life sign of low adaptation Increase adoption will increase quality of life A starting point for psychological therapy A low quality of life Malfunctioning of adaptation Wrong coping strategy Behavioral / peer group therapy Personality disorder More invasive therapy